TY - JOUR
T1 - Correction to
T2 - IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (Breast Cancer Research and Treatment, (2017), 165, 2, (343-353), 10.1007/s10549-017-4328-z)
AU - On Behalf Of The IrisTrial Participants
AU - Palmieri, Carlo
AU - Stein, Rob C.
AU - Liu, Xinxue
AU - Hudson, Emma
AU - Nicholas, Hanna
AU - Sasano, Hironobu
AU - Guestini, Fouzia
AU - Holcombe, Chris
AU - Barrett, Sophie
AU - Kenny, Laura
AU - Reed, Sadie
AU - Lim, Adrian
AU - Hayward, Larry
AU - Howell, Sacha
AU - Charles Coombes, R.
N1 - Funding Information:
In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.
Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.
AB - In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.
UR - http://www.scopus.com/inward/record.url?scp=85032226093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032226093&partnerID=8YFLogxK
U2 - 10.1007/s10549-017-4539-3
DO - 10.1007/s10549-017-4539-3
M3 - Comment/debate
C2 - 29071491
AN - SCOPUS:85032226093
SN - 0167-6806
VL - 167
SP - 407
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -
